Treatment of hepatitis C virus infection: updated Swedish Consensus recommendationsShow others and affiliations
2009 (English)In: Scandinavian Journal of Infectious Diseases, ISSN 0036-5548, E-ISSN 1651-1980, Vol. 41, no 6-7, p. 389-402Article in journal (Refereed) Published
Abstract [en]
In a recent expert meeting, Swedish recommendations for the treatment of HCV infection were upgraded. The panel recommends vaccination against both hepatitis A and B in patients with HCV. Therapy for symptomatic acute HCV infection should be initiated if spontaneous resolution has not occurred within 12 weeks, whereas asymptomatic acute HCV should be treated upon detection. Patients with genotype 2/3 infection should generally be treated for 24 weeks. In patients with a very rapid viral response (vRVR), i.e. HCV RNA below 1000 IU/ml on d 7, treatment can be shortened to 12-16 weeks, provided that no dose reduction has been made. For genotype 1 patients with rapid viral response (RVR), 24 weeks treatment is recommended. For patients with a complete early viral response (cEVR), 48 weeks treatment is recommended, whereas 72 weeks treatment should be considered for patients with partial early viral response (pEVR). For patients with difficult-to-treat disease and with pronounced anaemia, erythropoietin can be used to maintain the ribavirin dose. In HCV-HIV coinfected patients, combination therapy for HCV should, if possible, be initiated before anti-retroviral therapy (ART) is indicated. For liver transplant patients pre-emptive therapy is not recommended; hence, treatment should be deferred until histological recurrence.
Place, publisher, year, edition, pages
2009. Vol. 41, no 6-7, p. 389-402
Keywords [en]
Acute Disease; Adult; Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sweden
National Category
Infectious Medicine
Research subject
Infectious Diseases
Identifiers
URN: urn:nbn:se:oru:diva-37607DOI: 10.1080/00365540902998271ISI: 000268583000001PubMedID: 20001276Scopus ID: 2-s2.0-72149085994OAI: oai:DiVA.org:oru-37607DiVA, id: diva2:753495
Note
Additional participants in the Swedish Consensus Group: Kristina Bergström, Swedish Medical Products Agency, Uppsala; Pia Bylund, Swedish Medical Products Agency, Uppsala; Ann-Sofi Duberg, Department of Infectious Diseases, Örebro University Hospital, Örebro; Magnus Lindh, Departrment of Virology, Sahlgrenska University Hospital, Göteborg; Gunnar Norkrans, Department of Infectious Diseases, Sahlgrenska University Hospital, Göteborg; Olle Reichard, Department of Infectious Diseases, Karolinska University Hospital, Stockholm; Hans Verbaan, Department of Gastroenterology, Malmö University Hospital, Malmö; Ewa Wallmark, Department of Infectious Diseases, Malmö University Hospital, Malmö; Anders Widell, Department of Virology, Malmö University Hospital, MalmöRead More: http://informahealthcare.com/doi/abs/10.1080/00365540902998271
2014-10-082014-10-082023-01-20Bibliographically approved